title: No significant leukocytosis under controlled ovarian stimulation using the LHRH antagonist Cetrorelix and recFSH.
abstract: OBJECTIVE
  To study the influence of an LHRH (luteinizing hormone releasing hormone) antagonist protocol (Cetrorelix) and the use of recombinant follicle-stimulating hormone (FSH) on the development of leukocytosis, compared to the use of urinary HMG (human menopausal gonadotrophin).
  
  
  METHODS
  Prospective, randomized phase III clinical trial.
  
  
  METHODS
  Infertility day clinic, Department of Gynecology and Obstetrics.
  
  
  METHODS
  Thirty patients undergoing IVF/intracytoplasmic sperm injection (ICSI) treatment following controlled ovarian stimulation using a multiple dose protocol and the LHRH antagonist Cetrorelix.
  
  
  METHODS
  Differences in white blood cell (WBC) count before stimulation, during the follicular phase and in the midluteal phase.
  
  
  RESULTS
  Statistically significant increase in WBC count in the HMG group from the start of stimulation to the midluteal phase. No statistically significant increase in the recFSH group, but only a trend towards higher values was observed.
  
  
  CONCLUSIONS
  The development of a leukocytosis in controlled ovarian stimulation does not depend on the protocol used. Urinary gonadotrophins seem to have a greater potential to increase WBC count compared to recombinant gonadotrophins.
authors.affiliation: Department of Gynecology and Obstetrics, Medical University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. ludwig_m@t-online.de
authors.forename: M
authors.initials: M
authors.lastname: Ludwig
authors.forename: D
authors.initials: D
authors.lastname: Strik
authors.forename: R
authors.initials: R
authors.lastname: Felberbaum
authors.forename: S
authors.initials: S
authors.lastname: Al-Hasani
authors.forename: K
authors.initials: K
authors.lastname: Diedrich
mesh_terms: D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D007964:Leukocytosis / Q000209:etiology*; D008596:Menotropins / Q000652:urine; D010053:Ovary / Q000187:drug effects*; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D006727:Hormone Antagonists; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone; C062876:cetrorelix